Tag: preclinical
-
Antibodies Reduce Whooping Cough Severity, Infections
3 December 2015. Two engineered antibodies were shown in tests with lab animals to reduce the severity of whooping cough symptoms and white blood cell counts indicating infection. The team from the protein engineering lab of Jennifer Maynard at University of Texas in Austin and Synthetic Biologics, a biotechnology company in Rockville, Maryland, published its…
-
Chlamydia Vaccine Shown Working in Lab Tests
2 December 2015. An experimental vaccine to prevent chlamydia was shown in tests with lab mice to prevent pelvic inflammation and clear bacteria more than mice not receiving the vaccine. The vaccine, given through the nose, is made by NanoBio Corp., a biopharmaceutical company in Ann Arbor, Michigan. Chlamydia is a sexually transmitted disease that…
-
Licensing, Research Deal Aims at Chronic Wound Treatments
16 November 2015. Umeå University and the pharmaceutical company Prometic are partnering on development of new treatments for chronic wounds, such as diabetic foot ulcers and bed sores. The agreement gives Prometic, in Laval, Quebec, Canada an exclusive license to the university’s research on the blood plasma protein plasminogen, with the company funding further studies…
-
Compound Found to Reverse Lens Clouding in Cataracts
6 November 2015. A biochemical and medical research team discovered a steroid that when given as eye drops to mice, reverses the accumulation of protein formations in cataracts. Researchers from the labs of protein chemistry professor Jason Gestwicki at University of Michigan and ophthalmology professor Usha Andley at Washington University in St. Louis published their…
-
Two Current Drugs Shown Also to Promote Hair Growth
23 October 2015. Research originally designed to study hair loss from an autoimmune disorder, uncovered two drugs now on the market that in lab tests show they may also regrow hair. Findings of the study led by molecular dermatology professor Angela Christiano at Columbia University in New York appear in today’s issue of the journal…
-
Gates Grant Funding Whooping Cough Antibody Test
21 October 2015. A protein engineering lab at University of Texas in Austin is evaluating the potential of an engineered antibody to prevent pertussis, also known as whooping cough, among newborn infants. The study and lab are led by chemical engineering professor Jennifer Maynard, who is testing the antibody under a $400,000 grant from the…
-
Evotec, Foundation Partner on Rare Juvenile Disease
20 October 2015. The drug discovery company Evotec AG and Beyond Batten Disease Foundation are collaborating on discovery of new drugs to treat juvenile Batten disease, a rare inherited neurodegenerative disorder. Financial details of the partnership were not revealed. Batten disease is a rare genetic condition of the nervous system that in most cases begins…
-
Institute, GlaxoSmithKline ID Tuberculosis Candidates
13 October 2015. A biomedical research institute partnered with a lab backed by pharmaceutical company GlaxoSmithKline to identify candidates for drugs that act on bacteria causing tuberculosis. The team from Center for Infectious Disease Research in Seattle and Tres Cantos Open Lab Foundation, a lab in Spain sponsored by GlaxoSmithKline, published its findings in a…
-
Harvard Spin-Off Commercializing Sepsis Treatment
9 October 2015. A new enterprise spun-off from Harvard University is developing a device for treating sepsis, a life-threatening infection often contracted in hospitals. The company, Opsonix Inc. in Boston, also raised $8 million in its first round of venture funding. Opsonix is licensing a technology for treating sepsis developed in Harvard’s Wyss Institute for…
-
Eli Lilly Expanding NYC Labs for Cancer Therapies
9 October 2015. The pharmaceutical company Eli Lilly and Company is expanding its research labs in New York City to boost discoveries of cancer therapies that harness the immune system. Lilly expects to hire 50 more research and support staff as part of the expansion. The company’s new facility will inhabit 30,000 square feet in…